Mammary analog secretory carcinoma of the thyroid gland: A rare cancer harboring TRK fusion

• Published in: Oral oncology 2021-04, Vol.115, p.105092-105092, Article 105092
• Main Authors: Huang, Nai-si, Cao, Yi-ming, Lu, Zhong-wu, Guan, Qing, Chen, Jia-ying, Ma, Ben, Chen, Tong-zhen, Bai, Qian-ming, Wang, Yu-long, Ji, Qing-hai
• Format: Article
• Language: English
• Subjects: ETV6 rearrangement; Head and neck cancer; Mammary analog secretory carcinoma; Thyroid cancer; TRK inhibitor
• ISSN: 1368-8375; 1879-0593
• DOI: 10.1016/j.oraloncology.2020.105092

Mammary analog secretory carcinoma (MASC), or secretory carcinoma of the thyroid is an extremely rare disease harboring ETV6–NTRK3 gene fusion with TRK activation. Here we report the twelfth case of MASC of the thyroid worldwide. A 36-year-old female was diagnosed with poor-differentiated thyroid carcinoma (PDTC). Pathology consultant and immunochemical workups showed the tumor cells were negative for TTF1, TG, PAX8, positive for S100, Vimentin, GATA-3, and focally positive for mammaglobin. Fluorescence in situ hybridization (FISH) assay using a dual-color break-apart probe showed ETV6 translocation t(12p13) (ETV6) was present and established the diagnosis of MASC. Next-generation sequencing (NGS) of a 47-gene panel identified exon 1–5 of ETV6 gene were fused with exons 15–19 of NTRK3 gene. The patient experienced three loco-regional recurrences within 12 months and eventually developed inoperable local disease as well as bilateral lung metastasis. She is currently receiving anti-TRK treatment with a follow-up time of 33 months. A literature review of MASC in the thyroid was also conducted.